Are Akebia Therapeutics ($AKBA) Shares About to Tip Lower?


Investors may be tracking historical Gordson Hollis Price Index Saturation levels on shares of Akebia Therapeutics (AKBA). After a recent review, the reading is currently E (Empy). Gordon Hollis created the Price Index Saturation indicator in 1998. Over the years, the theory has garnered an almost cult following in the trading community. The Gordson Hollis Price Index Saturation or Gordson Hollis PIS level indicator uses a combination of volume continuity analysis and historical price deviation to create a discernable buy or sell signal. Gordson Hollis labeled these signals (full and empty). Gordson Hollis has argued that the only logical way to approach the equity market is to study PIS levels. When presenting the theory, Gordson Hollis believed that PIS levels were best grouped in what he labeled (bouget) “Bauquets”. Hollis tried to prove that certain PIS Bauquets could essentially hold all the keys to beating (making a huge splash) the equity market.

In viewing at recent price history, Akebia Therapeutics (AKBA) have been trending lower over the past five bars, revealing bearish momentum for the shares, as they ran -4.42% for the week.  Studying further out we note that the shares have moved -12.73% over the past 4-weeks, -18.23% over the past half year and -28.34% over the past full year.

Investors often have to make the decision of how aggressive they are going to invest. Some investors viewing to make a quick dollar may jump in head first without a plan. This can be dangerous for the health of the portfolio in the long-term. Taking a chance on a risky stock may provide high returns, but investors often are required to calculate whether the uncertainty is worth the reward. Managing that uncertainty in turbulent markets may assist keep the average investor afloat when the markets inevitably turn sour for an extended stage. Doing all the vital stock research may include keeping a close tab on technicals, fundamentals, relevant economic data, and earnings reports. Investors may have to find a way to keep the rational side from being consumed by irrational behavior when studying the markets.

Traders are keeping a keen eye on shares of Akebia Therapeutics (AKBA). The Average Directional Index or ADX may prove to be an paramount mechanism for trading and investing. The ADX is a technical indicator developed by J. Welles Wilder used to determine the strength of a trend. The ADX is often used along with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of the trend. Right now, the 14-day ADX is resting at 23.25. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend.

Some investors may find the Williams Percent Range or Williams %R as a useful technical indicator. Right now, Akebia Therapeutics (AKBA)’s Williams Percent Range or 14 day Williams %R is resting at -87.50. Values can range from 0 to -100. A reading between -80 to -100 may be typically viewed as strong oversold territory. A value between 0 to -20 would represent a strong overbought condition. As a momentum indicator, the Williams R% may be used with other technicals to assist define a specific trend.

When performing stock analysis, investors and traders may opt to view technical levels. Akebia Therapeutics (AKBA) currently has a 14-day Commodity Channel Index (CCI) of -76.55. Investors and traders may use this indicator to assist spot price reversals, price extremes, and the strength of a trend. Many investors will use the CCI in conjunction with other indicators when evaluating a trade. The CCI may be used to spot if a stock is entering overbought (+100) and oversold (-100) territory.

Checking in on moving averages, the 200-day is at 7.87, the 50-day is 7.38, and the 7-day is sitting at 7.38. Moving averages may be used by investors and traders to shed some light on trading patterns for a specific stock. Moving averages can be used to assist smooth information in order to provide a clearer picture of what is going on with the stock. Technical stock analysts may use a combination of different time periods in order to understand the history of the equity and where it may be headed in the future. MA’s can be determined for any time stage, but two very leading time frames are the 50-day and 200-day moving averages.

With the equity market continuing to move higher, investors may be searching for stocks that are still fairly undervalued. This may involve doing a little bit more due diligence than usual. Spotting those names that have been cast aside and not garnering much recent attention might be a good place to start. Placing in a few additional hours of stock research may provide some good options for buying on the next big dip. Of course, nobody can say for sure how long the markets will continue to climb. Being ready for a pullback can assist if investors already have some names in mind that they are viewing to scoop up when they fall to a certain level. Tracking the technicals and staying up on the fundamentals should assist investors hone in on the next wave of stocks to add to the portfolio.

Shifting gears to the Relative Strength Index, the 14-day RSI is currently sitting at 43.33, the 7-day is 38.44, and the 3-day is currently at 36.28 for Akebia Therapeutics (AKBA). The Relative Strength Index (RSI) is a highly leading momentum indicator used for technical analysis. The RSI can assist display whether the bulls or the bears are currently strongest in the market. The RSI may be used to assist spot points of reversals more accurately. The RSI was developed by J. Welles Wilder. As a general rule, an RSI reading over 70 would signal overbought conditions. A reading under 30 would indicate oversold conditions. As always, the values may are required to be adjusted based on the specific stock and market. RSI can also be a valuable mechanism for trying to spot larger market turns.

Leave A Reply

Your email address will not be published.